(Q36177848)

English

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

author name string

Martina Rebersek

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Marko Boc

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Petra Cerkovnik

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Jernej Benedik

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Zvezdana Hlebanja

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Neva Volk

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Srdjan Novakovic

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Janja Ocvirk

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

publication date

16 November 2011

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Radiology and Oncology

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

45

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

285-291

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Post-treatment surveillance in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

How to integrate molecular targeted agents in the continuum of care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Molecular origins of cancer: Molecular basis of colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Targeting signal transduction pathways in colorectal cancer--more than skin deep

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

Systemic therapy for colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

1 October 2017

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

1 reference

https://api.crossref.org/works/10.2478%2FV10019-011-0039-Y

21 January 2018

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

https://api.crossref.org/works/10.2478%2FV10019-011-0039-Y

21 January 2018

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

1 reference

https://api.crossref.org/works/10.2478%2FV10019-011-0039-Y

21 January 2018

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

23 September 2018

Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

23 September 2018

Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423757

23 September 2018

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

1 reference

https://api.crossref.org/works/10.2478%2FV10019-011-0039-Y

21 January 2018

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22933967

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BRAFMutation in Metastatic Colorectal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22933967

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22933967

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2478/V10019-011-0039-Y

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36177848&oldid=1991659397"